WallStSmart

Merck & Company Inc (MRK)vsMaravai Lifesciences Holdings Inc (MRVI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 32024% more annual revenue ($65.77B vs $204.73M). MRK leads profitability with a 13.6% profit margin vs -51.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

MRVI

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 2/9Altman Z: 0.32
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued

Intrinsic value data unavailable for MRVI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

MRVI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
40.5%10/10

Revenue surging 40.5% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MRVI4 concerns · Avg: 2.8/10
Operating MarginProfitability
1.1%3/10

Operating margin of 1.1%

Debt/EquityHealth
1.283/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-49.4%2/10

ROE of -49.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : MRVI

The strongest argument for MRVI centers on Revenue Growth. Revenue growth of 40.5% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : MRVI

The primary concerns for MRVI are Operating Margin, Debt/Equity, Piotroski F-Score.

Key Dynamics to Monitor

MRK profiles as a value stock while MRVI is a hypergrowth play — different risk/reward profiles.

MRVI carries more volatility with a beta of 0.65 — expect wider price swings.

MRVI is growing revenue faster at 40.5% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Maravai Lifesciences Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?